Clinical trials: Anticoagulant Drugs
Atrial Fibrillation
Electrophysiological Effects of NACOS and AVK on Pulmonary Veins and Left Atrium in Paroxysmal AF Catheter Ablation
Atrial fibrillation (AF) is the most common cardiac arrhythmias with a constantly growing prevalence AF. The purpose of paroxysmal AF processing is to control outbreaks from these pulmonary veins, medicated way (antiarrhythmic)…
- Trial name
- NACO-VP (NCT02814955)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Caen
Nurse Training
The Effect of Pecha-Kucha Method Training on the Knowledge and Skills of Nurses Regarding Anticoagulant Drug Administration
The research was conducted between January 2025 and May 2025 using a randomized controlled experimental design with a pre-test-post-test pproach.
- Trial name
- NCT07736326
- Testing
- Pecha-Kucha
- Where
- Turkey (Türkiye)
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Istanbul Saglik Bilimleri University
Stroke, Stroke (in Patients With Atrial Fibrillation)
Thrombolysis in Factor Xa-inhibitors Trial
This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT).
- Conditions
- Stroke, Stroke (in Patients With Atrial Fibrillation), Ischemic Stroke, Acute Ischemic Stroke
- Trial name
- SIFT (NCT06878066)
- Testing
- thrombolysis therapy
- Where
- 21 sites in Denmark, Norway and 1 more
- Volunteers
- 300 people
- Sponsor
- Guri Hagberg
Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous…
- Conditions
- Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders, Anticoagulation Treatment, Anticoagulant Therapy
- Trial name
- NCT06947707
- Where
- China
- Volunteers
- 1,486 people
- Sponsor
- Xuanwu Hospital, Beijing
Atrial Fibrillation, Stroke
Intention to Prescribe/Take OAC Depending on the Number of Risk Diagrams , and Period for the Estimation of the Risk.
Randomized study concerning the effect of the number of risk diagrams (with treatment +/- without treatment), the period of stroke risk estimation (one year or five years) and the target of prescription (the patient with atrial…
- Trial name
- NCT02746107
- Testing
- decision aid
- Where
- Romania
- Volunteers
- 968 people
- Sponsor
- Cristian Baicus
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Atrial Fibrillation
Clinical Trial for Optimal Novel Oral Anticoagulant (NOAC) Schedule Immediate Before Catheter Ablation for Atrial Fibrillation
This study is to evaluated the interruption schedule of NOAC in patients who undergo atrial fibrillation ablation. The investigators will compare the bleeding complications were classified as major and minor bleeding…
- Trial name
- NCT02504177
- Testing
- novel oral anticoagulant for 30 days, novel oral anticoagulant for 24 hour
- Where
- South Korea
- Volunteers
- 433 people
- Sponsor
- Yonsei University
Atrial Fibrillation, Myocardial Infarction
Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia
Patients with Acute Coronary Syndrome associated with de novo atrial fibrillation are randomized to benefit from either a conventional therapy associating dual antiplatelet therapy (DAPT) and anticoagulant or DAPT and an…
- Trial name
- SCA FA (NCT04276155)
- Testing
- non-systematic prescription of anticoagulant therapy
- Where
- 8 sites in France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier de PAU
Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive
Start or STop Anticoagulants Randomised Trial (SoSTART)
Primary research question: For adults surviving spontaneous (non-traumatic) symptomatic intracranial haemorrhage with persistent/paroxysmal atrial fibrillation/flutter (AF), does starting full treatment dose oral anticoagulation…
- Conditions
- Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive, Subarachnoid Hemorrhage, Subdural Hematoma
- Trial name
- SoSTART (NCT03153150)
- Testing
- Apixaban, Rivaroxaban, Edoxaban
- Where
- 67 sites in United Kingdom
- Volunteers
- 203 people
- Sponsor
- University of Edinburgh
Atrial Fibrillation
Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation
The primary purpose of this study (CLN-504) is to determine the safety and develop a dosing regimen of an investigational anticoagulant drug (ATI-5923) in patients with atrial fibrillation.
- Trial name
- NCT00431782
- Testing
- ATI-5923
- Where
- 11 sites in United States
- Volunteers
- 60 people
- Sponsor
- ARYx Therapeutics
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅰ (NCT06901466)
- Testing
- Experimental: Rivaroxaban monotherapy, Active Comparator: Rivaroxaban+Clopidogrel
- Where
- China
- Volunteers
- 880 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Anticoagulant Therapy
In Vitro Diagnostic Test for DOAC in Urine
This trial is conducted to assess the performance and handling of the in vitro diagnostic (IVD) device for oral direct factor Xa and thrombin inhibitors from urine samples of patients on treatment with direct oral anticoagulants…
- Trial name
- PADOASU (NCT03182829)
- Testing
- DOAC Dipstick
- Where
- 18 sites in Germany
- Volunteers
- 880 people
- Sponsor
- Doasense GmbH
Stroke, Atrial Fibrillation
Efficacy and Safety of Oral Anticoagulants Among Thai Octogenarians With Nonvalvular Atrial Fibrillation
A retrospective cohort study of Thai octogenarians with nonvalvular atrial fibrillation (NVAF) initiating apixaban, dabigatran, rivaroxaban or warfarin was conducted in medical school hospital in Thailand.
- Trial name
- NCT04047654
- Testing
- Non vitamin K oral anticoagulants
- Where
- Thailand
- Volunteers
- 327 people
- Sponsor
- Mahidol University
Stroke
Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.
AiCure uses artificial intelligence and visual recognition technology to confirm medication ingestion. The software is available as an app and downloaded onto a smart phone.
- Trial name
- NCT02599259
- Testing
- Monitored (M+)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- AiCure
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular…
- Trial name
- NCT00249873
- Testing
- clopidogrel (SR25990C)
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 7,554 people
- Sponsor
- Sanofi
Cardioembolic Stroke, Anticoagulant Therapy
Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke
This is an observational, prospective, multicenter, cohort study in patients with cardioembolic stroke and previous oral or parenteral anticoagulant therapy.
- Conditions
- Cardioembolic Stroke, Anticoagulant Therapy, Stroke Recurrence, Haemorrhagic Transformation Stroke
- Trial name
- KOALA-IS (NCT05486351)
- Testing
- Observation
- Where
- 3 sites in France, Spain
- Volunteers
- 318 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Atrial Fibrillation, Thromboembolism
A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
This study is to assess the safety of a potential new drug DU-176b for the prevention of stroke/systemic embolic event (SEE) in individuals with non-valvular atrial fibrillation (AF).
- Trial name
- NCT00504556
- Testing
- Edoxaban (DU-176b), warfarin
- Where
- 91 sites in United States, Belarus and 10 more
- Volunteers
- 1,146 people
- Sponsor
- Daiichi Sankyo
Venous Thromboembolism (VTE), Cancer
Vortosiran for VTE Prevention
Blood clots remain a serious cause of illness and death. Long-term treatment and prevention of these clots with blood thinners is often limited by bleeding risk, drug interactions, and daily dosing, leading many patients to stop…
- Conditions
- Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis)
- Trial name
- NCT07850453
- Testing
- Vortosiran
- Where
- 30 sites in Bulgaria, France and 2 more
- Volunteers
- 150 people
- Sponsor
- Ribocure Pharmaceuticals AB
Anticoagulants; Increased
Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage
Randomized pilot trial of restarting DOACs at 1 week versus 4 weeks after traumatic intracranial hemorrhage
- Trial name
- NCT04891861
- Testing
- Apixaban
- Volunteers
- 100 people
- Sponsor
- University of Texas at Austin
Atrial Fibrillation
Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04593030
- Testing
- Warfarin, Apixaban
- Where
- United States
- Volunteers
- 220,518 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital